A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Attack Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oral Ubrogepant In The Acute Treatment Of Migraine With Or Without Aura In Children And Adole
Posted Date: Jan 19, 2022
- Investigator: Luis Patino Duran
- Specialties:
- Type of Study: Drug
Study drug for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Criteria:
Participants Must Be Between The Ages Of 6 And 17 Years (Inclusive), Have A History Of Migraine With Or Without Aura For At Least 6 Months
Keywords:
Acute Migraine, Children, Aura
For More Information:
Heather Williamson, Mcr
513-558-6612
woodalhe@ucmail.uc.edu